Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001193125-21-328063 0001609492 XXXXXXXX LIVE 7 Common Shares 01/31/2025 false 0001808158 760273102 REPARE THERAPEUTICS INC. 7171 FREDERICK BANTING SUITE 270, BUILDING 2 SAINT-LAURENT A8 H4S 1Z9 Ansbert Gadicke 617-425-9200 c/o MPM BioImpact LLC 339 Boylston Street, Suite 1100 Boston MA 02116 0001609492 N MPM BioVentures 2014, L.P. b WC N DE 1018345.00 0.00 1018345.00 0.00 1018345.00 N 2.4 PN 0001609493 N MPM BioVentures 2014 (B), L.P. b WC N DE 67921.00 0.00 67921.00 0.00 67921.00 N 0.2 PN 0001609495 N MPM Asset Management Investors BV2014 LLC b WC N DE 35052.00 0.00 35052.00 0.00 35052.00 N 0.1 OO 0001691428 N UBS Oncology Impact Fund L.P. b WC N E9 819924.00 0.00 819924.00 0.00 819924.00 N 1.9 PN 0001765091 N MPM BioVentures 2014 GP LLC b WC N DE 0.00 1086266.00 0.00 1086266.00 1086266.00 N 2.6 OO 0001765021 N MPM BioVentures 2014 LLC b WC N DE 0.00 1121318.00 0.00 1121318.00 1121318.00 N 2.6 OO 0001721036 N Oncology Impact Fund (Cayman) Management L.P. b WC N E9 0.00 819924.00 0.00 819924.00 819924.00 N 1.9 PN 0001687078 N MPM BioImpact LLC b WC N DE 0.00 819924.00 0.00 819924.00 819924.00 N 1.9 OO 0001134655 N ANSBERT GADICKE b WC N X1 0.00 1941242.00 0.00 1941242.00 1941242.00 N 4.6 IN 0001134657 N LUKE EVNIN b WC N X1 0.00 1121318.00 0.00 1121318.00 1121318.00 N 2.6 IN 0001473930 N Todd Foley b WC N X1 0.00 1121318.00 0.00 1121318.00 1121318.00 N 2.6 IN Common Shares REPARE THERAPEUTICS INC. 7171 FREDERICK BANTING SUITE 270, BUILDING 2 SAINT-LAURENT A8 H4S 1Z9 Explanatory Note: This Amendment No. 7 to Schedule 13D ('Amendment No. 7') is being filed as an amendment to the initial statement on Schedule 13D relating to the common shares (the 'Common Shares'), of Repare Therapeutics Inc. (the 'Issuer'), as filed with the Securities and Exchange Commission (the 'SEC') on July 6, 2020, as amended by Amendment No. 1 filed March 23, 2021, Amendment No. 2 filed May 25, 2021, Amendment No. 3 filed July 21, 2021, Amendment No. 4 filed December 26, 2024, Amendment No. 5 filed January 6, 2025 and Amendment No. 6 filed January 15, 2025 (as amended, the 'Original Schedule 13D'). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales of the Issuer's Common Shares by certain Filing Persons. Items 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 7 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D. See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 7 for the aggregate number of Common Shares and percentages of the shares of Common Shares beneficially owned by the Filing Person. The Common Shares are held as follows: * 1,018,345 shares are held directly by BV 2014; * 67,921 shares are held directly by BV 2014(B); * 35,052 shares are held directly by AM BV2014 LLC; and * 819,924 shares are held directly by UBS Oncology. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B). BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC. BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology. Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC. Dr. Gadicke is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology. Calculation of the percentage of the shares of Common Shares beneficially owned is based upon 42,510,708 Common Shares outstanding as of November 1, 2024, as reported in the Issuer's Form 10-Q filed with the SEC on November 7, 2024. See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 7 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition. The Filing Persons sold the following Common Shares in the open market since the date of filing Amendment No. 6: Date of Sale Price Range Ave. Price Sold by Sold by Sold By AM BV Sold by BV 2014 BV 2104(B) 2014 LLC UBS Oncology 1/16/25 $1.255-$1.32 $1.27 10,326 689 356 8,314 1/17/25 $1.2599-$1.2901 $1.28 20,071 1,339 690 16,160 1/21/25 $1.22-$1.31 $1.24 16,024 1,069 551 12,902 1/22/25 $1.20-$1.235 $1.22 19,017 1,268 655 15,312 1/23/25 $1.155-$1.22 $1.20 21,705 1,448 746 17,476 1/24/25 $1.20-$1.26 $1.23 5,796 387 199 4,667 1/27/25 $1.15-$1.2034 $1.18 16,265 1,085 560 13,096 Inapplicable. All Filing Persons ceased to be the beneficial owners of more than five percent of the Common Shares on January 17, 2025. Joint Filing Statement MPM BioVentures 2014, L.P. /s/ Ansbert Gadicke Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P. 01/31/2025 MPM BioVentures 2014 (B), L.P. /s/ Ansbert Gadicke Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P 01/31/2025 MPM Asset Management Investors BV2014 LLC /s/ Ansbert Gadicke Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC 01/31/2025 UBS Oncology Impact Fund L.P. /s/ Ansbert Gadicke Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P. 01/31/2025 MPM BioVentures 2014 GP LLC /s/ Ansbert Gadicke Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC 01/31/2025 MPM BioVentures 2014 LLC /s/ Ansbert Gadicke Managing Director 01/31/2025 Oncology Impact Fund (Cayman) Management L.P. /s/ Ansbert Gadicke Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P. 01/31/2025 MPM BioImpact LLC /s/ Ansbert Gadicke Managing Partner 01/31/2025 ANSBERT GADICKE /s/ Ansbert Gadicke Ansbert Gadicke 01/31/2025 LUKE EVNIN /s/ Luke Evnin Luke Evnin 01/31/2025 Todd Foley /s/ Todd Foley Todd Foley 01/31/2025